Quantification of the associations between biomolecules is required both to predict and understand the interactions that underpin all biological activity. Fluorescence polarization (Fp) provides a nondisruptive means of measuring the association of a fluorescent ligand with a larger molecule. We describe an Fp assay in which binding of fluorescein-labeled inositol 1,4,5-trisphosphate (Ip 3 ) to n-terminal fragments of Ip 3 receptors can be characterized at different temperatures and in competition with other ligands. the assay allows the standard Gibbs free energy (DG°), enthalpy (DH°) and entropy (DS°) changes of ligand binding to be determined. the method is applicable to any purified ligand-binding site for which an appropriate fluorescent ligand is available. Fp can be used to measure low-affinity interactions in real time without the use of radioactive materials, it is nondestructive and, with appropriate care, it can resolve DH° and DS°. the first part of the protocol, protein preparation, may take several weeks, whereas the Fp measurements, once they have been optimized, would normally take 1-6 h. We can measure the K D of a bimolecular interaction by measuring the two rate constants (k + 1 and k − 1 ) or, more easily, by measuring the saturable relationship between [D] and [DR] at equilibrium (Fig. 1a) . The latter requires that we identify, without appreciably perturbing the equilibrium, the small fraction of D that has bound to R (a small fraction because we usually ensure that D T >> R T ).
IntroDuctIon
Life, from the simplest bacterium to the most complex multicellular animal, depends on specific interactions between molecules. Replication and decoding of genetic material, for example, require selective pairing of nucleotide sequences guided by specific interactions with proteins. Assembly of the macromolecular complexes that establish cellular architecture and the biochemical pathways that sustain cells are each determined by selective interactions between proteins, nucleic acids and lipids. Every biochemical step within a cell, from enzyme catalysis to ion transport and receptor activation, is initiated by specific interactions between a macromolecule and a ligand. The latter (from ligo, to bind) has come to mean rather different things to chemists and biologists. In this study, we define a ligand as any species (ion, molecule and so on) that binds selectively, stoichiometrically and reversibly to a larger molecule, usually a macromolecule such as DNA or protein. The interactions between biomolecules are determined by their concentrations (and therefore their subcellular distributions) and by the strength of the interactions between them. Quantitative analysis of the interactions between biomolecules is therefore central to understanding every aspect of cellular behavior. The rates of the two reactions are given by the products of the concentrations of the reactants (denoted [D] ; abbreviations and definitions are listed in , their association will significantly affect the free concentration of only the less concentrated reactant (R in this case). However, if the total concentrations of the partners are both similar and sufficient to allow them to bind (D T ≈ R T > K D ), their association will significantly reduce the free concentration of both. In cells, both situations occur. However, in most experimental analyses of ligand binding, conditions are chosen to ensure that the concentration of one reactant substantially exceeds that of the other. For conventional analyses of radioligand binding to receptors, for example, the concentration of radioligand (D T ) used considerably exceeds the total concentration of receptors (R T ), such that no matter how many receptors bind the ligand, the free concentration of ligand is not significantly changed 1, 2 . [DR]/R T is the fractional occupancy (often abbreviated as α). We now have a means of determining K D by measuring how α varies (1) (1) (2) (2) as a function of [D] (Fig. 1a) . Note that when α is 0. 5 
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(i.e., 50% of R have bound D), [D] = K D . Also note how [D] is invariably expressed relative to its affinity for R (i.e., [D]/K D ).
We can measure the K D of a bimolecular interaction by measuring the two rate constants (k + 1 and k − 1 ) or, more easily, by measuring the saturable relationship between [D] and [DR] at equilibrium (Fig. 1a) . The latter requires that we identify, without appreciably perturbing the equilibrium, the small fraction of D that has bound to R (a small fraction because we usually ensure that D T >> R T ).
Not all binding reactions are so simple. Binding sites may interact (cooperativity), or the initial complex of ligand and receptor may undergo conformational changes or interact with additional partners that influence the strength of the binding event 3, 4 . These are important issues, but they need not deflect us from the focus of this protocol, which is to describe the practicalities of measuring the K D for a simple ligand-receptor interaction.
Thermodynamic analysis of protein-ligand interactions
The K D provides a measure of the strength of the interaction between the two partners and allows us to predict how their association will change as their concentrations vary (Fig. 1a) . We can also interpret the K D from a thermodynamic perspective and, with appropriate experiments, determine the contributions of standard enthalpy (∆H°) and entropy (∆S°) changes to the binding event.
The second law of thermodynamics, and thereby the relationships between the standard Gibbs free energy change (∆G°), ∆H°, ∆S° and K D , provides the route to these analyses 5 :
here R is the universal gas constant and T is the absolute temperature. The second law, which dictates that reactions proceed spontaneously in the direction of decreasing free energy (∆G < 0; Fig. 1b ), makes the relationship between ∆G° and K D intuitively clear 5, 6 . When there is no difference in free energy between reactants and products, there is no driving force for their association or dissociation (∆G° = 0 and so K D = 1). When the products have more free energy than the reactants, the driving force is toward dissociation (∆G° > 0, K D > 1), but when the reactants have more free energy than the products, the driving force is toward association (∆G° < 0, K D < 1; Fig. 1b) .
It is not easy to relate the two components of ∆G°, ∆H° and T∆S°, specifically and directly to binding mechanisms [7] [8] [9] . Broadly, ∆H° reflects energy changes associated with making ( − ∆H°) and breaking ( + ∆H°) bonds, whereas ∆S° reflects changes associated with increasing ( + ∆S°) or decreasing ( − ∆S°) the number of microscopic configurations available to the system. Therefore, ∆S° reflects the extent to which binding changes features such as the conformational flexibility or mobility of the reactants, products and solvent. Empirically, it has been reported that for some ligandreceptor interactions, the relative contributions of ∆H° and ∆S° to binding may distinguish those ligands that activate a receptor (agonists) from those that bind without activating (competitive antagonists) 7, 10 . Clearly, measurements of K D (and so ∆G°) are not alone sufficient to resolve the contributions from ∆H° and ∆S°. This requires either measurements at different temperatures or direct measurement of ∆H° ( Table 2 ).
Methods to measure ligand binding
Among the factors to consider when deciding on the most suitable method for quantitative analysis of a protein-ligand interaction are the following:
1. Does the analysis need to be performed in an intact cell or can it be performed in a disrupted system? 2. Is the interaction strong enough (more specifically is k − 1 slow enough) to allow separation of free and bound ligand without appreciably perturbing the equilibrium? 3. Does the interaction require use of an unmodified ligand or are modified ligands (e.g., radioactive, fluorescent and so on) available and useful? 4. If the method requires purified protein, is it functional and available in sufficient quantity?
5. Is measurement of the K D sufficient or is there also a need to determine either rate constants (k + 1 and k − 1 ) or ∆H° and ∆S°?
The means by which bound ligand is detected divides the methods into two broad categories ( Table 2 ). The first requires that bound and free ligand are separated (usually by filtration or centrifugation), whereas the second detects bound ligand without physically separating it from the free ligand. The latter can measure even low-affinity interactions, because there is no separation step during which fast ligand dissociation (large k − 1 ) might perturb the equilibrium. These methods quantify bound ligand by directly measuring ∆H (isothermal titration calorimetry (ITC)), by detecting the increase in size of the protein-ligand complex (fluorescence polarization, FP; surface plasmon resonance; and fluorescence correlation spectroscopy), by bringing the ligand into contact with a sensor when it binds to an immobilized protein (scintillation proximity assay; total internal reflection fluorescence microscopy) or by detecting a change in fluorescence lifetime (fluorescence lifetime imaging microscopy) or fluorescence spectrum (fluorescence resonance energy transfer) when a fluorescent ligand associates with a protein, which must itself be fluorescent for fluorescence resonance energy transfer. The advantages and limitations of these different methods are compared in Table 2 .
Protein-ligand interactions analyzed by FP
When a rigid and entirely immobile fluorophore is excited (typically in 10 − 15 s) by plane-polarized light, it emits light in orientations that depend on the angle (ζ) between the orientations of the absorbing and emitting dipoles 11 :
. If the dipoles are parallel (ζ = 0°), for example, then A = 0.4 (i.e., 60% of the emitted light would be detected in the same plane as that of the exciting light, and 20% in each of the other two planes; Fig. 2a) . If there were no rotation of such a molecule during the lifetime of the excited state of the fluorophore (typically ns), then the maximal value of A would be 0.4. However, if the molecule rotates (less than ns timescales for small molecules), it will no longer be aligned, and when the fluorophore emits its light, < 60% will be aligned with the source (Fig. 2a) . The speed at which the fluorophore tumbles (defined by its rotational relaxation time, ρ) relative to the lifetime of its excited state (the interval between absorbing and emitting ) to a larger protein using plan-polarized light to detect the change in effective molecular volume 18, 40 ( a photon) will determine whether rotation of a molecule can be detected 12 . FP measures the light emitted from a fluorescent ligand in two planes (horizontal and vertical) after excitation with planepolarized light in one of these planes (Fig. 2b) where ρ is the rotation relaxation time (time taken for the molecule to rotate through 68.5°); V, molecular volume; η, viscosity; and R and T have their usual meanings. With other conditions constant, the speed of tumbling is inversely related to molecular volume. A large molecule is, therefore, likely to retain the same orientation during the interval (~4 ns for fluorescein) 13 between absorbing and emitting a photon, whereas a smaller one is more likely to re-orient. 
where F F and F B are the fractions of free and bound D*, respectively (F F + F B = 1). This then provides the basis for using FP as a nondisruptive assay of ligand binding (Fig. 2c) . Although the method is applicable to analyses of binding of any small fluorescent ligand to any larger molecule 14 , we focus on ligand binding (D) to a receptor (R). There are, however, three important differences between FP analyses and conventional assays of radioligand binding that influence both experimental design and analysis. First, FP requires a fluorescent ligand (D * ). Second, although FP does not require separation of bound and free D * , it does require that we distinguish them by fluorescence. Third, FP analyses require that a substantial amount of D * is bound to R to provide a measurable change in A. Therefore, we cannot assume, as we do with radioligand-binding assays, that D
The effects of these differences on the design of FP experiments are described in Box 1.
Applications of FP assays FP-binding assays can, in principle, be used quantitatively to analyze binding of any small soluble fluorescent molecule (and any soluble ligand that competes with it) to a larger soluble protein.
The suitability of FP assays to high-throughput screening, using relatively inexpensive equipment, has lead to their use in screening programmes in drug discovery and as 'off-the-shelf ' assay kits for a variety of biomolecules. The former include development of inhibitors of interactions between proteins and either small molecules [15] [16] [17] [18] [19] or other proteins 20 . Use of FP to detect antibody-antigen interactions 21 has provided many opportunities to adapt FP assays for bioassay of enzyme activity 22 , bioactive proteins 23 , and intracellular messengers 24 and metabolites 25 . Our FP assay was developed to (6) (6) (9)), it is important to stress that A NS must be separately calculated for each measurement of A in which [D * ] varies. A, due to specific binding of D * (A S ), can then be calculated:
Distinguishing bound from free ligand
The aim of every binding assay is to quantify the amount of D * bound to R without perturbing the equilibrium (Fig. 1a) . For radioligand-binding assays, this presents a challenge because bound and free D * must be separated (usually by centrifugation or filtration) quickly enough to avoid significantly perturbing the equilibrium (table 2) . Thereafter, quantification is straightforward because only bound D * is trapped on the filter or in the pellet (and where necessary, corrections for trapped volume can easily correct for residual free D * ). The situation is different for FP. Here there is no need to separate bound from free D * (Fig. 2c) , and so no risk of perturbing the equilibrium, but the measured anisotropy (A M ) includes that from free D * , that bound specifically to R (D * R) and that bound nonspecifically. There are, therefore, two practical issues. First, FP requires that there is no change in the behavior of the fluorophore (e.g., quenching) when D * binds; D * must behave as an inert reporter of molecular rotation (Fig. 2c) . We need, therefore, to verify that the fluorescence intensity of D * is unaffected by binding (box 3). Second, we need to relate the measured anisotropy (A M ), from which we derive anisotropy due to specific binding (A S , equation (11) (11) (12) (12) allow analysis of interactions between N-terminal (NT) fragments of the IP 3 R and small-molecule agonists. It can also be used to assay levels of endogenous IP 3 extracted from biological samples 24 .
Advantages and limitations of FP assays
FP assays do not require separation of bound and free ligand. This allows ligand binding to be quantified without perturbing the equilibrium, making it suitable for measurement of lowaffinity interactions (more specifically, interactions with fast dissociation rates). Although the initial optimization of FP assays is likely to be time-consuming, thereafter they are easily automated. They can, therefore, provide high-throughput, economical, rapid and convenient screens for large numbers of unlabeled ligands. FP assays are non-destructive, thereby allowing repetitive measurements of the same sample under different conditions (e.g., different temperatures). Such analyses, which would usually be impracticable with radioligand-binding assays, allow the contributions from ∆H° and T∆S° to ∆G° to be resolved. Other methods, such as ITC ( Table 2) , can provide more direct, and perhaps more reliable, access to these thermodynamic characteristics of protein-ligand interactions, but they require large amounts of pure protein and more costly equipment. FP assays avoid routine use of radioligands, with consequent financial, health and environmental benefits. All FP assays require a fluorescent ligand. This may be available commercially or it may require development of procedures for conjugation of the ligand to a reactive fluorophore (many of these are available from Invitrogen, SigmaAldrich and other suppliers) and subsequent purification of the conjugate. It may even be necessary (as it was with the FITC-IP 3 used in our assay) to synthesize a form of the ligand suitable for (12)) to the free concentrations of D * and R (Fig. 1a) , we must calculate the relationships between their total and free concentrations for each incubation. Here we encounter a third feature that distinguishes radioligand from FP analyses. With ) and the error will be < 5%. This requirement is equivalent to that imposed in radioligand-binding experiments, in which we usually aim for < 10% of D * being bound.
(13) (13) (14) (14) conjugation 18 . Whereas radiolabeling of a ligand (particularly with 3 H) is unlikely to affect its interaction with a target protein, fluorophores are likely to affect the interaction. In the worst-case scenario, it may be impracticable to obtain a fluorescent ligand that interacts effectively with a target protein; FP would then be impossible. Every FP assay requires accurate quantification of the concentration of functional binding sites. This is manageable when relatively few proteins are to be used to screen a battery of ligands, but it may become impracticable if the aim is to screen a large number of proteins (e.g., mutants). FP assays are more demanding than radioligand binding in the amount of protein they require, but less so than other techniques such as surface plasmon resonance or ITC. Specialized, although relatively inexpensive, equipment is required for FP and available equipment can often be used for other optical assays as well. Finally, FP assays are applicable only to soluble partners and only for fluorescent ligands that are considerably smaller than the protein to which they bind. Table 2 compares the advantages and limitations of the most common methods used to characterize protein-ligand interactions.
IP 3 receptors
Our use of FP to measure ligand binding has focused on inositol 1,4,5-trisphosphate receptors (IP 3 Rs). Before exploring the method, we therefore provide some essential background information on these intracellular Ca 2 + channels 26 . IP 3 Rs are expressed in the membranes of the endoplasmic reticulum of most, if not all, animal cells. They mediate the initial release of Ca 2 + from intracellular stores evoked by the many cell-surface receptors that stimulate IP 3 formation. Because IP 3 Rs are also regulated by the Ca 2 + they release, they can also initiate regenerative Ca 2 + signals, allowing the initial openings of a few IP 3 Rs to grow into Ca 2 + waves that may invade the entire cell 27, 28 . The important point is that activation of all IP 3 Rs is initiated by IP 3 binding; this then promotes Ca 2 + binding, which then leads to opening of the Ca 2 + -permeable pore. All IP 3 Rs are large tetrameric proteins, each subunit of which includes a very large cytoplasmic region, six transmembrane domains toward the C terminus that contribute to the pore and a short C-terminal tail (Fig. 3a) . The IP 3 -binding core (IBC, residues 224-604 of IP 3 R) of each subunit is entirely responsible for binding IP 3 . A highresolution structure of the IBC shows IP 3 cradled within a clam-like structure lined with many basic residues (Fig. 3b) (ref. 29) . The structural details of the steps linking IP 3 binding to opening of the pore remain largely speculative, but it seems clear that residues within the extreme N terminus that form the so-called suppressor domain (residues 1-223) are essential 4 . Two points are important for the method described herein. First, the IBC expressed as a soluble protein in bacteria recognizes IP 3 and related ligands with the same specificity as native IP 3 Rs 4, 30 . Second, the conformational changes initiated by IP 3 pass from the IBC through the suppressor domain to the pore, allowing the initial activation process to be examined in a soluble, bacterially expressed NT fragment of the IP 3 R (ref. 4). We use both IBC and NT fragments to show the utility of FP for analyses of ligand binding 18 .
Experimental design Protocol overview. The protocol is divided into two parts: (i) preparation of protein and (ii) FP measurements and their analysis (Fig. 4) . The first part includes cloning, expression of protein in bacteria, protein purification and quantification of functional binding sites.
Optimization. The steps must be optimized for each protein and fluorescent ligand. Before scaling up protein expression methods, pilot experiments are recommended to optimize the choice of purification strategy (which may require engineered tags), conditions for protein expression (e.g., growth and induction temperatures, For expression of NT fragments of IP 3 Rs, we began with a published protocol 22 and then introduced some modifications 4 . Similar adaptations of existing protocols are likely to provide the most economical route to expression of other proteins for FP analysis. Our purification strategy used a glutathione-S-transferase (GST) tag provided by a pGEX-6P-2 vector and glutathione sepharose 4B beads for affinity purification. The tag is then removed by cleavage at a PreScission cleavage site. For other proteins, a variety of commercially available tags (e.g., poly-His, biotin) and cleavage sites (e.g., thrombin, enterokinase) offer many opportunities to optimize purification strategies. In deciding between tags and cleavage sites, it is important to consider whether they affect protein expression or function, and whether there are any possible endogenous sites for the cleavage enzyme. The FP assay then requires quantitative measurement of functional ligand-binding sites. After purification, the protein concentration must be determined using a standard assay, for example, the Bradford 31 or bicinchoninic acid assays 32 or their many convenient commercial derivatives. If western blot and silver-staining analyses identify only a single band, the total protein concentration defines the concentration of the protein of interest. However, in bacterial expression systems there are often several smaller fragments, and even if these are absent some of the full-length proteins may not be functional. It is therefore essential to quantify directly the concentration of the functional protein. This is best achieved with a conventional radioligand-binding assay using, for example, centrifugation to separate bound from free radioligand after precipitation of the soluble protein 4 . This definitive measure of the concentration of functional binding sites ) is essential for FP analyses (Boxes 1 and 2) . It is worth comparing this measurement with quantification of silver-stained gels to estimate the fraction of the appropriately sized protein that is functional. There are many options for quantifying bands within gels: we use GeneSnap image acquisition software from Syngene, but ImageJ software is a freely available alternative (http://rsbweb. nih.gov/ij/). From the total protein concentration of the sample (in mg ml − 1 ) and quantification of the relative amount of protein within the band of appropriate size (67 kDa for the NT fragment of IP 3 R) on a silver-stained gel (in %), the concentration of the 67-kDa protein in the sample can be calculated (mg ml − 1 ). Because there is one IP 3 -binding site in each NT fragment, this concentration of the 67-kDa protein (mg ml − 1 ) can be compared with the concentration of IP 3 -binding sites in the same sample (nmol mg − 1 ) and with the theoretical density of IP 3 -binding sites if each were functional (~15 nmol mg − 1 ). From these calculations, the fraction of the protein within the 67-kDa band that retains a functional IP 3 -binding site can be estimated. This provides an index of the quality of the protein preparation. For other proteins too it is essential to develop methods to quantify the concentration of functional protein, and ideally to assess its purity.
The FP assay needs to be optimized for each protein-ligand interaction (Box 3). First, it is necessary to assess whether the fluorescence of the ligand changes when it binds to the protein.
It is essential for FP analyses that only the rate of depolarization, but not the fluorescence intensity, changes after binding (Box 2). If binding affects the fluorescent properties of the fluorophore, the latter should be conjugated through another position, or use of another fluorescent ligand and/or protein fragment should be explored. Second, the optimal concentration of fluorescent ligand for an FP assay needs to be determined. This can be achieved by measuring A of serially diluted concentrations of fluorescent ligand and choosing the lowest concentration (to keep it below its K D ) that allows A to be measured reliably free of contributions from background fluorescence (Box 3). Third, it is necessary to establish whether high protein concentrations (independent of their ability to bind to the ligand) interfere with detection of the polarized light (e.g., by absorption). The assay is therefore performed under conditions in which a large excess of unlabeled ligand prevents binding of the fluorescently labeled ligand to the protein. If any attenuation of detected light is the same in both planes (I || and I  ), it will not affect the measurement of A. Otherwise a correction will be required. These optimization steps are described in detail in 18 , it will not affect the measurement of A. Otherwise a correction will be required.
of the competition assay. In practice, a protein concentration that gives A > 50% of A D*R is a reasonable target (Box 2). The time taken for incubations to reach equilibrium depends on the protein and the ligand, their concentrations and the temperature; it needs to be determined for each set of conditions. Further details of both types of FP assay are provided in Boxes 1 and 2.
Equipment requirements. FP measurements require a microplate reader capable of resolving FP. Suitable equipment is available from several suppliers, including BMG Labtech, BioTek and Berthold Technologies. Most companies offer multimode microplate readers, which can be used for additional applications (e.g., luminescence, time-resolved fluorescence and so on). For FP measurements, samples are excited with plane-polarized light (horizontally or vertically, depending on the equipment) at the excitation wavelength of the fluorophore. Emitted light is simultaneously measured in the parallel (I || ) and the perpendicular (I  ) planes, relative to the excitation source (Fig. 2b) . Most instruments provide direct readouts of both A and polarization. We use the Pherastar (BMG Labtech). The choice of excitation and emission filters and dichroic mirror is dictated by the excitation and emission spectra of the fluorophore. The intensity of light detected by the two photomultiplier tubes is used to determine A (equation (5)). The default FP setting for the Pherastar is 'plate-mode' , in which each cycle reads the entire plate (rather than a single well). The direction in which the plate is read (e.g., left to right) is programmable and selected to best match the layout of samples in the 96-well plate (we use direction 11). The Pherastar moves the plate to align each well with the light path before each reading; a programmable 'positioning delay' (minimum 300 ms) allows this to be adjusted to ensure that the fluid has settled before data collection (we set the delay to 1 s). The optimal 'focal height' at which readings are taken depends on the microplates and volumes of fluid. The automatic adjustment (recommended) reads samples at various heights to determine the optimal height for the maximal signal. We read the entire plate three times for each assay, with no lag between cycles (if appropriate, it is possible to program an interval between cycles; see Step 47) . Each cycle averages the signal from a programmed number of flashes from the light source: more flashes increase accuracy, but at the expense of longer read times. We choose 300 flashes per cycle (Step 47). The gain on each photomultiplier tube must be adjusted to avoid saturation and to balance their sensitivities. If A D* is known, the gains are adjusted to give the expected A D* using a sample with the highest [D * ]. In practice, the Pherastar uses polarization (P, see INTRODUCTION) rather than A: for fluorescein, P = 0.035, and for FITC-IP 3 , P = 0.025 (ref. 18) . These values are set as the target values during the automated gain adjustment. The built-in temperature-controlled chamber of the Pherastar can maintain temperatures from ~5 °C above ambient to 45 °C. For lower temperatures, the entire apparatus must be housed in a temperature-controlled cabinet.
Results analysis.
A spreadsheet (e.g., Excel), which may initially take 1-2 h to prepare, provides the most economical means of preparing results for analysis. Results can then be imported directly from the equipment and analyzed quickly. We use GraphPad Prism version 5 to fit results to Hill equations, but other curve-fitting programs can also be used (e.g., MATLAB, Origin).
MaterIals
REAGENTS
1,4-Piperazinediethanesulfonic acid (PIPES; Sigma-Aldrich, cat. no. P1851) 2-Mercaptoethanol (Gibco, cat. no. 31350-010) Adenophostin A (Fig. 3c) . 3c ) was synthesized and purified as described in reference 18. They should be black to reduce cross-talk between wells; half-area to minimize reaction volume; polystyrene to minimize nonspecific binding; and round bottomed for optimal mixing. Depending on the light path of the optical system (Fig. 2b) (Fig. 2b) . Aluminum foil Pipettes (8-or 12-channel; e.g., Pipetman ultra multi-channel: F21040 (8 × 20 µl), F21041 (12 × 20 µl), F21042 (8 × 300 µl) and F21043 (12 × 300 µl), Gilson) Autoclave (e.g., Crystal 200, Rodwell Scientific Instruments) Benchtop centrifuge for 96-well plates (e.g., ALC PK120 plate centrifuge, DJB Labcare) Curve-fitting software (e.g., GraphPad Prism 5, GraphPad Sofware) End-over-end rotation apparatus (e.g., Rotospin test tube rotator, Tarsons) iBlot gel-transfer device (Invitrogen, cat. no. IB1001) iBlot transfer stack, PVDF mini (Invitrogen, cat. no. IB4010-02) Liquid scintillation counter (e.g., LS 6500 scintillation counter, Beckman) Liquid-handling system (e.g., CAS-1200, Corbett Robotics UK). This is not essential. pH meter (e.g., routine pH electrode and meter, Mettler Toledo) Plate reader capable of FP measurements (e.g., Pherastar, BMG Labtech) (for further details of equipment requirements, see Fig. 2b and INTRODUCTION) Power supply for electrophoresis and transfer device (e.g., PowerPac basic power supply, BioRad)
• proceDure cloning of nt fragments of Ip 3 rs • tIMInG 7 d 1| Use Platinum Pfx DNA polymerase (or other available thermostable DNA polymerase) to amplify NT fragments of rat IP 3 R1. As template, use the full-length rat type 1 IP 3 R clone lacking the S1 splice site with primers P1 and P2 for the NT (residues 1-604) and P2 and P3 for the IBC (residues 224-604). The sequences of the primers are listed in table 3. The fragments are numbered with reference to the full-length (S1 + , i.e., with the S1 splice site) rat IP 3 R1 (GenBank accession number: GQ233032.1). For each set of primers, set up the reaction as follows: 6| Plate-transform cells on LB-agar plates containing ampicillin (final concentration, 100 µg ml ) and grow for ~12 h at 37 °C to select ampicillin-resistant clones.
7|
Pick colonies (~10 per plate) and incubate each in 2 ml of LB containing ampicillin (final concentration, 100 µg ml − 1 ) for ~12 h at 37 °C. Pellet cells by centrifugation (6,000g for 5 min) and purify plasmid DNA using a standard miniprep plasmid purification kit (e.g., QIAprep spin miniprep kit), following the manufacturer's instructions.
8|
Verify identity of the purified plasmid DNA (from Step 7) by restriction enzyme digestion. For each plasmid, add 1 µg of plasmid DNA, 1 µl of 10× buffer, 0.5 µl of each restriction enzyme and dH 2 O to a final volume of 10 µl. The same restriction enzymes used for cloning can be used for digestion. Incubate for 1 h at 37 °C. Run digested products (10 µl of each product and 2 µl of 6× gel-loading dye in an ethidium bromide-stained 1% (wt/vol) agarose gel for ~20 min to check for bands of appropriate size. Confirm sequences of all constructs by DNA sequencing. ! cautIon Ethidium bromide is a mutagen and suspected carcinogen. Use gloves, avoid contamination and contact with skin.
9|
Use QuikChange II XL site-directed mutagenesis kit to insert the S1 splice site (residues 318-332) into the pGEX-IBC construct (from Step 8) . Set up each reaction exactly as described in Step 1, using the purified plasmid DNA from Step 8 as template DNA and primers P4 and P5 ( 11| Add 1 µl of the DpnI restriction enzyme to the amplification reaction (from Step 10). Mix and incubate at 37 °C for 1 h to digest the parental DNA.
12| Transform 2 µl of the digested product into XL10-Gold ultracompetent cells provided with the kit, following the manufacturer's instructions. Plate transform cells in LB plates containing ampicillin (final concentration, 100 µg ml − 1 ) and incubate for ~12 h at 37 °C to select the ampicillin-resistant clones.
13|
Pick up colonies (approximately five colonies per clone) and incubate each in 2 ml of LB medium containing ampicillin (final concentration, 100 µg ml − 1 ) for ~12 h at 37 °C. Pellet cells by centrifugation (6,000g for 5 min) and purify plasmid DNA using a standard miniprep plasmid purification kit (e.g., QIAprep spin miniprep kit), following the manufacturer's instructions. Confirm sequences of all constructs by DNA sequencing. expression of Ip 3 r fragments • tIMInG 3 d 14| Transform pGEX-NT and pGEX-IBC (from Steps 8 and 13, respectively) into competent E. coli AVB101 (or other competent E. coli strain such as BL21 D3) by a standard heat-shock method 34 .
15| Plate-transform cells on LB-agar plates containing ampicillin (100 µg ml − 1 ) and incubate overnight at 37 °C.
16| Inoculate a single colony in 2 ml of LB medium containing ampicillin (final 100 µg ml − 1 ) and incubate in an orbital shaker at 250 r.p.m. for ~12 h at 37 °C.
17| Inoculate 1 ml of the culture (from Step 16) into 100 ml of LB medium containing ampicillin (final concentration, 100 µg ml − 1 ). The cultures can be scaled up to provide the amount of protein required.
18|
Grow the cultures (from Step 17) in an orbital shaker (~150 r.p.m.) at 22 °C until the OD 600 (optical density at 600 nm) reaches about 1-1.5 (after ~7 h). These conditions (notably the incubation temperature of 22 °C, rather than 37 °C used for expression of most proteins) are specifically optimized for expression of N-terminal fragments of IP 3 Rs.  crItIcal step It is necessary to optimize growing conditions uniquely for each protein. 
21|
Resupend the pellet in 4.4 ml of ice-cold TEM containing protease inhibitor cocktail (Roche protease inhibitor cocktail tablet complete mini, 1 tablet per 10 ml). Vortex until the pellet is fully resuspended.
22|
Add 0.5 ml of PopCulture (final concentration, 10% (vol/vol)) and 100 µl of 50 mM 2-mercaptoethanol (final concentration, 1 mM) to the resuspended pellet (from Step 21) . Incubate the suspension with lysozyme (5 µl of a solution of 100 mg ml 
26|
Transfer the gel onto a PVDF membrane with the iBlot gel-transfer device, according to the manufacturer's instructions. Western blot is performed using anti-GST antibody (1:3,000) (ref. 36 ) and goat anti-rabbit antibody (1:5,000) (Fig. 5a ) 4 . The western blot will reveal whether protein of the expected size has been successfully expressed.
purification of Ip 3 r fragments • tIMInG 8 h 27|
If the protein lysate (from Step 23) has been frozen (Step 24), thaw it on ice and then centrifuge at 30,000g for 30 min at 4 °C to clear the supernatant.  crItIcal step This clearance step is essential to remove debris.
28|
Gently shake the glutathione Sepharose 4B beads to resuspend the medium. Transfer 665 µl of the slurry (which is ~75%) to a 50-ml tube. Sediment the slurry by centrifugation at 500g for 5 min. Aspirate the supernatant carefully and discard.
29|
Wash the glutathione Sepharose 4B beads by adding 10 ml of cold PBS and separate beads by centrifugation at 500g for 5 min. Aspirate the supernatant carefully and discard. Repeat this wash twice more.
30|
Add 500 µl of cold PBS to the washed and sedimented glutathione Sepharose 4B beads (from Step 29) to give a 50% slurry; add 50 ml of the cleared lysate (from Step 23 or Step 27) to the 50% slurry and mix by gentle inversion.
31| Incubate the mixture from
Step 30 for 30 min at ~22 °C with gentle (~6 r.p.m.) end-over-end rotation. Pour the mixture into an empty PD-10 column. Tap the column and allow the beads to settle.  crItIcal step The efficiency of binding to glutathione Sepharose 4B beads can differ considerably between different GST-tagged proteins. Optimal incubation conditions need to be determined for each protein.
 crItIcal step All procedures hereafter should be performed at 4 °C to minimize protein degradation.
32|
Open the column outlet and allow the column to drain. Save an aliquot (~50 µl) of the flow-through for analysis of nonretained proteins by electrophoresis and Coomassie staining (Step 40).
? troublesHootInG 33| Close the column outlet and wash the drained beads (from Step 32) by adding 10 ml of Ca 2 + -free CLM containing DTT (final concentration, 1 mM) to the column. Incubate for 5 min with gentle end-over-end rotation. Open the column outlet and allow the column to drain. Save an aliquot (~50 µl) of the flow-through for analysis by electrophoresis and Coomassie staining (Step 40).  crItIcal step Washing the glutathione Sepharose 4B beads after protein binding is important to ensure purity of NT-tagged GTS fragments.
34|
Repeat wash (Step 33) four times. Save aliquots (~50 µl) from each wash step for analysis by electrophoresis and Coomassie staining (Step 40).  crItIcal step After the final wash, ensure that the column drains completely to avoid dilution of the final eluate (Step 36).
35|
Prepare PreScission protease mix by adding 40 µl (80 U) of PreScission protease to 460 µl of cold Ca 2 + -free CLM supplemented with 1 mM DTT. Load the PreScission protease mixture onto the column from Step 34.
36|
Seal the column and incubate with gentle end-over-end rotation for ~12 h at 4 °C.  crItIcal step The optimal conditions for cleavage (e.g., amount of enzyme, time and temperature) need to be determined uniquely for each protein in pilot reactions.
37|
Open the column outlet and collect the eluate, which contains purified IP 3 R fragments. PreScission enzyme is GST tagged, so it remains bound to the column. Save aliquots (~50 µl) for analysis by electrophoresis and Coomassie staining 43| Perform silver-staining of one gel according to the manufacturer's instructions (Fig. 5a) . Transfer the other gel to a PVDF membrane using the iBlot system following the manufacturer's instructions and western blot with appropriate antisera. We use rabbit antisera (1:1,000) raised to peptides corresponding to residues 62-75 (ref. 37) or 326-343 (the SI splice site) 4 of IP 3 R1 for NT and IBC fragments, respectively. The secondary antibody is horseradish peroxidase-conjugated goat anti-rabbit antibody (1:5,000) (Fig. 5a) .  crItIcal step If the 'purified protein' appears as a single band on the silver-stained gel and western blot (Step 43), proceed directly to Step 45. It is more likely, however, that the preparation contains the IP 3 R fragment contaminated by other minor protein bands.
Step 44 is then required to define exactly the concentration of IP 3 R fragment within the preparation. It is essential to know precisely the concentration of functional ligand-binding sites for FP analyses (box 1). ? troublesHootInG 44| Quantify the intensity of all bands in each lane for each protein in both silver-stained gels and western blots. Use ImageJ (freely available from: http://rsbweb.nih.gov/ij/docs/menus/analyze.html gelsusing) or custom software (e.g., Genetools), provided by the manufacturer of the gel quantification software (e.g., Synegene)). Calculate the percentage of total protein (from the silver-stained gel) present in the band corresponding to the NT (~67 kDa) or IBC (~43 kDa). A third identical set of serially diluted NT (final concentration, 1-300 nM), but without FITC-IP 3 . This allows background fluorescence (I || and I  ) at each concentration of NT to be determined (columns I-L in Fig. 6 ). In cases in which these values are significant, they should be subtracted from the equivalent measurements with FITC-IP 3 present before computing A (Step 50). FITC-IP 3 (final concentration, 0.5 nM) alone to allow A D* (the anisotropy of free D * ) to be determined (wells C8 and D8 in Fig. 6 ).  crItIcal step Each of these conditions must be included in every plate.  crItIcal step The method is described for assays using the NT. For assays with the IBC (which binds most ligands with 10-fold lower K D than does the NT) 4 , use ~10-fold lower concentrations of binding site. (ii) Gently shake the plate (30 r.p.m.) for 15 min at ~22 °C using an orbital shaker or the orbital shaking mode in the Pherastar plate reader. Centrifuge at 300g for 2 min at ~22 °C.  crItIcal step Keep plates and samples wrapped in foil to minimize exposure of fluorescent reagents to light. (iii) Incubate the plate in the dark at the temperature under investigation (typically 4-37 °C) for 20 min for equilibrium to be attained. Measure I || and I  using the Pherastar plate reader (Steps 47-49). After collection of measurements at one temperature, the instrument and plate can be re-equilibrated to another temperature, and the measurements of I || and I  repeated on the same samples 18 .  crItIcal step The time taken for incubations to reach equilibrium must be optimized for each set of conditions. ? troublesHootInG  crItIcal step The concentrations of the competing ligand should ideally cover a range of at least 100-fold on either side of its K D . The method is described for assays using NT. For assays with the IBC, use ~10-fold lower concentrations of protein and competing ligand.  crItIcal step Protein concentration needs to be optimized for each condition.
(ii) Gently shake the plate (30 r.p.m.) for 15 min at ~22 °C using an orbital shaker or the orbital shaking mode in the Pherastar plate reader. Centrifuge at 300g for 2 min at ~22 °C. (iii) Incubate the plate in the dark at the temperature at which the measurements will be made for 20 min for equilibrium to be attained. Measure I || and I  using the Pherastar plate reader (Steps 47-49).  crItIcal step The time taken for incubations to reach equilibrium must be optimized for each set of conditions. ? troublesHootInG anisotropy measurements • tIMInG 15 min-6 h 47| Open the Pherastar software and select the FP option. Insert the FP 485/520/520 optic module. Set Pherastar options as follows: three cycles of measurement; 300 flashes per cycle; 1 s positioning delay; reading direction 11 (for details of these settings, see Fig. 2 and EXPERIMENTAL DESIGN).
48|
Perform auto-adjustment of focal height and gain in the well containing 50 µl of 0.5 nM FITC-IP 3 . Set the 'mP Target' value to 25. The focal height for 50 µl of solution in a half-area well should be ~6.3.  crItIcal step Optimal adjustment of gain and focal height is essential to achieve maximal sensitivity.
49|
Use these settings (Steps 47 and 48) to measure the entire plate (set up as described in Step 46) . Samples are excited with horizontally polarized light at 485 nm, and emission is simultaneously measured at 520 nm in the horizontal (i.e., parallel, I || ) and vertical (i.e., perpendicular, I  ) planes (Fig. 2b) .  crItIcal step For measurements at different temperatures, the plate reader must be housed in a temperature-controlled cabinet. Allow ~2-3 h for the reaction chamber to cool to 4 °C. Incubate the plate for 20 min at each temperature to allow the reaction to attain equilibrium before measurements.
? troublesHootInG analysis • tIMInG 1 h 50| For each experimental measurement, subtract the background I || and I  due to the presence of the protein alone (Step 46). From equation (5), calculate A M using these corrected values of I || and I  .
51|
Calculate A I similarly (using equation (5) R9   R10 R10  R10  R10  R10  R10   R11  R11  R11  R11  R11  R11   R12  R12  R12  R12  R12   R13  R13  R13  R13   R14 R14  R14 R14  R14 R14   R15  R15 R15  R15 R15  R15   D*  D*   R12   R13  R13   R3  R3  R3  R3  R3  R3   R4  R4  R4  R4  R4  R4   R5  R5  R5  R5   R6  R6  R6  R6  R6  R6   R7  R7  R7  R7  R7  R7   R8  R8  R8  R8  R8  R8   R5  R5   R9  R9  R9  R9  R1   R2  R2  R2  R2  R2  R2   R1  R1  R1  R1  R1  1   2   3   4   5   6   7   8 Figure 6 | Typical 96-well plate layout for the FP saturation binding assay. All wells in columns A to H contain FITC-IP 3 (0.5 nM). Protein dilutions (1-300 nM) are labeled R1-R15. Columns A to D include no further additions (allowing A M to be determined); columns E to H also include a saturating concentration of IP 3 (10 µM, allowing A NS to be determined). Columns I to L include only the serial dilutions of protein (to allow background fluorescence to be measured). Wells C8 and D8 include only FITC-IP 3 (to allow A D* to be determined). Further details are given in Step 46A. The layout is typical, but it is advisable to vary the layout between experiments to avoid systematic errors in automated pipetting.
at each protein concentration using equations (9) and (10) (13) and (14)), plot A S against R T (~[R]) to provide a typical binding curve (Fig. 1a) . If R T is too low to avoid a significant decrease in [R] as D * binds, [R] must be calculated for each condition (box 1, equation (14)) before plotting the binding curve. In either case, any suitable curve-fitting program (we use GraphPad Prism version 5) can be used to fit the results to a Hill equation:
where α is the fraction of D * specifically bound, and h is the Hill coefficient. ) is then calculated using equation (17)).
56|
For experiments performed at different temperatures, the K D can be calculated from saturation (Step 53) or competition (
Step 55) binding experiments at each temperature. Equations (3) and (4) define the relationships between K D , ∆G°, ∆S° and ∆H°. If ∆H° is temperature independent (i.e., the change in heat capacity, ∆C = 0), a van't Hoff plot (lnK D versus 1/T) can be used to obtain ∆H°/R from the slope. If ∆C ≠ 0 the following equation is used 38 :
where T is the actual absolute temperature and T 0 is the reference absolute temperature (296 °K in our experiments). ∆H°, ∆S° and ∆C° are determined by least-squares curve-fitting of ∆G° versus T. ) are very low, because the incubations must be performed at lower than normal incubation temperatures (Step 19) (ref. 35) . For both the NT and IBC, the full-length fragments are expressed with smaller NT-tagged products 4, 35 . These shorter fragments are also collected in the eluates (Steps 37-39) after purification with glutathione Sepharose 4B beads (Fig. 5a) . Western blots and silver-staining of 'purified' NT (from Step 40) show that ~37 ± 9% of the total protein has the size expected of the NT (Fig. 5a) . Similar results were obtained with the IBC 18 . Because the relative intensities of the major bands are similar whether identified by silver staining or western blotting with antibodies to near-NT epitopes (see Step 44) , it seems likely that the shorter fragments are C-terminally truncated products. From our knowledge of the minimal requirements for IP 3 binding 4, 18 , it is clear that these truncated products could not bind IP 3 . Therefore, the truncated fragments are unlikely to contribute to specific binding of FITC-IP 3 in the FP assay 18 . In parallel comparisons from the same preparation of 'purified' NT, equilibrium competition and saturation radioligand-binding assays using 5) . These values also agree with published results 39 . Figure 7a shows an example of a typical equilibrium saturation curve using our FP assay with FITC-IP 3 (final concentration, 0.5 nM) and increasing concentrations of purified NT. The nondestructive nature of the FP assay in combination with its ability to detect low-affinity interactions is particularly useful for analyses of the effects of temperature on ligand binding 18 . A single 96-well plate can be used to measure the K D (and so ∆G°, equation (3)) at multiple temperatures (allowing computation of ∆H° and ∆S°, equation (4)), thereby considerably reducing both the variability introduced by plate-to-plate differences and use of precious materials (notably purified protein). For example, in a typical 96-well plate format for an equilibrium competition FP-binding assay, we obtain K D values for three different ligands from a single plate (with duplicate determinations of 15 concentrations for each ligand) at six different temperatures in < 3 h. Similar experiments using radioligand-binding assays would be prohibitively costly, the fast off-rates (k − 1 ) would make them almost impracticable, and they would take days to complete. Before relying on repetitive measurements from the same plate, it is necessary to show that the effects of temperature are fully reversible. In equilibrium competition FP assays, the K D of IP 3 for the NT (K D = 89 ± 7 nM) at 4 °C was indistinguishable from that obtained when the same plate was incubated at 37 °C (K D = 490 ± 40 nM) and then returned to 4 °C (K D = 86 ± 9 nM), nor did the K D of IP 3 for the NT change over the time (~2 h) taken to complete the measurements at different temperatures 18 . These results confirm the stability of the assay and have also allowed us to determine ∆H° and ∆S° for binding of different ligands to NT fragments of the IP 3 R (Fig. 7c) 
18
. Adenophostin A 0.7 ± 0.1 0.9 ± 0.1 6.2 ± 1.6 8.6 ± 0.2
The K D (nM) for each ligand determined in Ca 2 + -free CLM at 4 °C by equilibrium competition binding assays using 3 H-IP 3 or by FP is shown as mean ± s.e.m., n = 3. Results are taken from reference 18 with permission from The American Society for Pharmacology and Experimental Therapeutics.
